RCUS
Arcus Biosciences·NYSE
--
--(--)
--
--(--)
4.75 / 10
Netural
Analyst coverage is lukewarm, with Morgan Stanley issuing a downgrade and Goldman Sachs maintaining a Strong Buy, resulting in a 1.96 weighted rating and a netural consensus. Fund-flow analysis shows a 7.53/10 score with positive small-cap inflows but negative trends in larger blocks, hinting at short-term liquidity support yet persistent selling pressure.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-13
InstitutionGoldman Sachs
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for RCUS?
- RCUS holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.75/10 (Netural).
